What is Effexor and how does it affect weight gain? Discover the facts about Effexor and weight changes, common side effects, and tips for managing weight while taking this antidepressant medication.

Understanding Effexor: An Overview

Effexor, the brand name for the antidepressant medication venlafaxine, is commonly prescribed to treat symptoms associated with depression and anxiety disorders. It works by regulating the levels of neurotransmitters like serotonin and norepinephrine in the brain, which can help improve mood and alleviate various mental health conditions.

The Relationship Between Effexor and Weight Gain

One of the potential side effects of taking Effexor is weight gain. Studies have shown that newer antidepressant drugs, including Effexor, may be associated with significant weight gain in some patients. However, the research on the topic is mixed, with some studies indicating only a small or insignificant impact on weight.

It’s important to note that the effect of antidepressants on weight is complex and can be influenced by factors such as the individual’s underlying mental health condition, eating habits, and physical activity levels. Depression itself can also lead to changes in appetite and weight, independent of the medication.

Common Side Effects of Effexor

In addition to potential weight gain, Effexor can cause a variety of other side effects, including:

• Dizziness
• Blurred vision
• Fatigue
• Dry mouth
• Insomnia or difficulty falling asleep
• Gastrointestinal issues (e.g., heartburn, decreased appetite, constipation, gas, diarrhea)
• Vivid or unusual dreams
• Chills
• Decreased sex drive or difficulty achieving orgasm or ejaculation
• Sweating
• Prickly or tingling sensations

Many of these side effects are often mild and tend to subside within a few weeks as the body adjusts to the medication.

Managing Weight Changes While Taking Effexor

If you experience weight gain while taking Effexor, it’s important to work closely with your healthcare provider to monitor your progress and adjust your treatment plan as needed. Some strategies that may help manage weight changes include:

• Maintaining a balanced, healthy diet and regular exercise routine
• Monitoring your appetite and making adjustments to your food intake as needed
• Considering the timing of your medication and any potential impact on appetite or energy levels
• Discussing alternative treatment options with your doctor, if the weight gain is a significant concern

It’s essential to communicate openly with your healthcare provider about any side effects you experience, including changes in weight, to ensure you receive the best possible care and support.

When to Seek Medical Attention

If you experience severe or persistent side effects while taking Effexor, or if you have concerns about your weight or overall health, it’s important to consult with your healthcare provider. They can help determine the appropriate course of action, which may include adjusting your medication dosage, trying alternative treatments, or addressing any underlying health concerns.

Weighing the Risks and Benefits

When starting a new medication like Effexor, it’s normal to have concerns about potential side effects, including weight gain. However, it’s important to remember that the positive effects of the medication, such as improved mood and reduced anxiety, often outweigh the negative side effects for many patients. Your healthcare provider can help you weigh the risks and benefits of taking Effexor and develop a treatment plan that best suits your individual needs and goals.

Conclusion

Effexor, a commonly prescribed antidepressant, can potentially lead to weight gain in some patients. However, the research on this topic is mixed, and the effect of antidepressants on weight is complex, influenced by various factors. By working closely with your healthcare provider, monitoring your progress, and implementing healthy lifestyle strategies, you can manage any weight changes that may occur while taking Effexor. Remember, open communication with your doctor is key to ensuring you receive the best possible care and support throughout your treatment.

Effexor Weight Gain: What You Should Know

When starting a new medication, it’s normal to feel anxious about how your body may react.

The prospect of experiencing side effects can be daunting, and depression and the medications used to treat it can affect your appetite and body weight in unwanted ways.

While side effects can range from annoying to scary, it’s also important to note that most of the time, the positive effects of the medication outweigh the negative. 

In this article, we’ll review a common side effect of antidepressants: weight gain, specifically in the context of Effexor.

We’ll review what Effexor is, the relationship between this medication and weight gain, and common side effects when taking it.

We’ll also go over precautions and when to see a doctor. 

What is Effexor?

Effexor (venlafaxine) is an antidepressant that is commonly prescribed to treat symptoms associated with depression and anxiety.

Effexor helps relieve symptoms that may occur with depression and anxiety, like sadness, hopelessness, guilt, and lack of interest in things that once brought you joy.

It can also be used to treat physical manifestations of anxiety, including nausea, jitters, or restlessness, amongst other things. 

Feeling Down?

Take our free assessment and learn about your options.

Get Started

Effexor uses

Effexor is used to treat anxiety disorders, panic disorders, social phobia disorder, as well as major depressive disorder.

It can also be prescribed as a mood stabilizer, as well as used to treat post-traumatic stress disorder, bipolar disorder, and attention-deficit hyperactivity disorder. 

Other studies show that venlafaxine is effective in treating nerve pain, migraines, and tension headaches.

It has also been prescribed to treat hot flashes as a result of menopause or chemothrapy.

These are “off label” uses, meaning the FDA has not approved them for these diseases but prescribers can decide if it’s appropriate for individual patients.

How Effexor works

Antidepressants work by affecting the chemicals in the brain known as neurotransmitters.

These include the managing of available levels of serotonin, norepinephrine, and dopamine.

Effexor is part of a class of drugs known as SNRIs (serotonin-norepinephrine reuptake inhibitor), which regulate the amount of serotonin and norepinephrine molecules in the brain by blocking the reabsorption or reuptake of such chemicals.

This makes more of these chemicals available in the brain and results in mood regulation.

Effexor and Weight Gain

Many antidepressant and anxiety medications list weight gain as a potential side effect.

This is the case with Effexor as well, but not everyone experiences such side effects. 

What the research says

Studies show that newer antidepressant drugs may be associated with weight gain.

In one such study, venlafaxine was associated with significant weight gain, alongside citalopram (Celexa), escitalopram (Lexapro), sertraline (Zoloft), and paroxetine (Paxil).

Some studies and clinical studies show that patients treated with Effexor gain a significant amount of weight, while other studies show that weight gain from venlafaxine is small and potentially insignificant.  

While studies show that some antidepressants may cause weight gain, the effect of antidepressants on weight is still mixed and needs further examination. 

Common Side Effects of Effexor

Like many medications, there are a variety of side effects that may occur when taking Effexor.

These side effects are often mild, and a doctor will usually prescribe a low dose to start and build up slowly to a higher daily dose to avoid significant side effects.

Many of the side effects should go away within a few weeks. 

Common side effects include:

• Dizziness
• Blurred vision
• Fatigue
• Dry mouth
• Insomnia or difficulty falling asleep
• Gastrointestinal issues like heartburn, decreased appetite, constipation, gas, or diarrhea
• Vivid or unusual dreams
• Chills
• Decreased sex drive or difficulty achieving orgasm or ejaculation
• Sweating
• Prickly or tingling sensations

Depression and Weight Changes

There are a number of signs of depression.

A common one to look out for is appetite changes.

This may include a noticeable weight gain or loss.

This may occur in both clinically depressed, as well as “high functioning” depression. 

Those who are depressed may be less likely to make healthy eating choices, which may affect one’s weight more than a medication itself.

Depression also affects energy levels and your desire to do things that you once enjoyed.

This may affect one’s desire to exercise regularly, an important part of maintaining a healthy body weight. 

How to Take Effexor

Effexor is often taken daily with a starting dose of 37.5 mg per day, which is increased over time to 75 mg daily, a common dosage to treat depression, generalized anxiety, panic disorders, and social anxiety disorder.

Your doctor may adjust your dosage over time, but they do not usually recommend going over 225 mg per day. 

Effexor Precautions

Before starting Effexor, tell your doctor about all medications and supplements you take, as some can interact with the medication and cause serious side effects.

Especially in the beginning, it is best to avoid alcohol, as venlafaxine can make you drowsy. 

Before stopping Effexor, consult your doctor and they will help you wean off the medication.

Sudden and immediate stopping can cause withdrawal side effects like nausea, vomiting, headache, and irritability. It’s best to stop taking Effexor with the help of a psychiatrist. 

Feeling Down?

Take our free assessment and learn about your options.

Get Started

When to See a Doctor

Speak with your doctor about what antidepressant medication is right for you.

If your side effects worsen or symptoms don’t begin to resolve in 6 weeks, you may want to try a different dose of medication. 

Contact a doctor immediately if you suspect signs of an overdose, which includes dizziness, flashes of hot and cold, dilated pupils, irregular heart rate, and seizures. 

With drugs that affect the serotonin levels in your brain, there is a risk of serotonin syndrome.

This is when your body has too much serotonin and requires immediate medical attention.

Symptoms include restlessness, insomnia, confusion, high blood pressure, sweating, diarrhea, headache, and goosebumps. 

If you experience serious side effects, including suicidal thoughts or worsening symptoms of depression, talk to someone immediately, such as calling a suicide crisis line like 988.

How K Health Can Help

Think you might need a prescription for Effexor (Venlafaxine)?

K Health has clinicians standing by 24/7 to evaluate your symptoms and determine if Effexor is right for you.

Get started with our free assessment, which will tell you in minutes if treatment could be a good fit. If yes, we’ll connect you right to a clinician who can prescribe medication and have it shipped right to your door.

Frequently Asked Questions

Will Effexor help me lose weight?

Side effects vary from patient to patient, but neither weight loss nor weight gain is guaranteed when taking antidepressants. Additionally, Effexor is not amongst the list of antidepressants that have been connected to weight loss, which include bupropion (Wellbutrin), fluoxetine (Prozac), and duloxetine (Cymbalta). The best way to lose weight is to make healthy lifestyle and eating choices, which can include managing caloric intake.

Has anyone gained weight on venlafaxine?

Weight gain is a possible side effect accompanied with taking venlafaxine, but side effects vary depending on the patient. The bottom line is that while some people may gain weight, there is no way to know whether you will experience such a side effect.

Is it hard to lose weight on venlafaxine?

While some patients in one study found it difficult to lose weight during and after taking venlafaxine, this is not a universal experience and will differ from patient to patient. If you’re having trouble losing weight on venlafaxine, seek the help of a registered dietitian.

Does Effexor affect appetite?

Decreased appetite is one of the possible and common side effects of Effexor. This may affect your weight, but will likely resolve as your body adjusts to the medication.

K Health articles are all written and reviewed by MDs, PhDs, NPs, or PharmDs and are for informational purposes only. This information does not constitute and should not be relied on for professional medical advice. Always talk to your doctor about the risks and benefits of any treatment.

K Health has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions,
and medical associations. We avoid using tertiary references.

• Low-Dose Estradiol and the Serotonin-Norepinephrine Reuptake Inhibitor Venlafaxine for Vasomotor Symptoms. (2014.)
  https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1876676

• A drug combination that reduces weight gain associated with antidepressant therapy.
  https://otc.duke.edu/technologies/a-drug-combination-that-reduces-weight-gain-associated-with-antidepressant-therapy/

• Weight gain and associated factors in patients using newer antidepressant drugs. (2014.)
  https://pubmed.ncbi.nlm.nih.gov/25467076/

• Antidepressants cause minimal weight gain. (2014.)
  https://www.health.harvard.edu/blog/antidepressants-cause-minimal-weight-gain-201406067202

• Serotonin Syndrome. (2013.)
  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865832/

Weight gain and associated factors in patients using newer antidepressant drugs

. 2015 Jan-Feb;37(1):46-8.

doi: 10.1016/j.genhosppsych.2014.10.011.

Epub 2014 Oct 31.

Faruk Uguz 
¹
, Mine Sahingoz 
²
, Buket Gungor 
³
, Fadime Aksoy 
⁴
, Rustem Askin 
⁵

Affiliations

Affiliations

• ¹ Department of Psychiatry, University of Necmettin Erbakan, Meram Faculty of Medicine, Konya, Turkey. Electronic address: [email protected].
• ² Department of Psychiatry, University of Necmettin Erbakan, Meram Faculty of Medicine, Konya, Turkey. Electronic address: [email protected].
• ³ Department of Psychiatry, Sevket Yilmaz Research and Training Hospital, Bursa, Turkey. Electronic address: [email protected].
• ⁴ Department of Psychiatry, University of Necmettin Erbakan, Meram Faculty of Medicine, Konya, Turkey. Electronic address: [email protected].
• ⁵ Department of Psychiatry, Sevket Yilmaz Research and Training Hospital, Bursa, Turkey. Electronic address: [email protected].

• PMID:

  25467076

• DOI:

  10. 1016/j.genhosppsych.2014.10.011

Faruk Uguz et al.

Gen Hosp Psychiatry.

2015 Jan-Feb.

. 2015 Jan-Feb;37(1):46-8.

doi: 10.1016/j.genhosppsych.2014.10.011.

Epub 2014 Oct 31.

Authors

Faruk Uguz 
¹
, Mine Sahingoz 
²
, Buket Gungor 
³
, Fadime Aksoy 
⁴
, Rustem Askin 
⁵

Affiliations

• ¹ Department of Psychiatry, University of Necmettin Erbakan, Meram Faculty of Medicine, Konya, Turkey. Electronic address: [email protected].
• ² Department of Psychiatry, University of Necmettin Erbakan, Meram Faculty of Medicine, Konya, Turkey. Electronic address: [email protected].
• ³ Department of Psychiatry, Sevket Yilmaz Research and Training Hospital, Bursa, Turkey. Electronic address: [email protected].
• ⁴ Department of Psychiatry, University of Necmettin Erbakan, Meram Faculty of Medicine, Konya, Turkey. Electronic address: [email protected].
• ⁵ Department of Psychiatry, Sevket Yilmaz Research and Training Hospital, Bursa, Turkey. Electronic address: [email protected].

• PMID:

  25467076

• DOI:

  10.1016/j.genhosppsych.2014.10.011

Abstract

Objective:

The aim of the present study was to examine weight gain and its association with clinical and sociodemographic characteristics in patients using newer antidepressants.

Methods:

The study had a cross-sectional design. A total of 362 consecutive psychiatric patients taking antidepressant drugs for 6 to 36 months were included in the study.

Results:

The prevalence rate of weight gain was 55.2%; 40.6% of the patients had a weight gain of 7% or more compared to the baseline. Overall, antidepressant use was significantly related to increased body weight. Specifically, citalopram, escitalopram, sertraline, paroxetine, venlafaxine, duloxetine and mirtazapine, but not fluoxetine, were associated with significant weight gain. Multivariate logistic regression analysis indicated that lower education status, lower body mass index at the onset of antidepressant use and family history of obesity were independent predictors of weight gain ≥7% compared to the baseline.

Conclusions:

The study results suggest that patients who take newer antidepressants might have significant problems related to body weight.

Keywords:

Antidepressants; Body mass index; Weight gain.

Copyright © 2015 Elsevier Inc. All rights reserved.

Similar articles

• Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose?

  Bateman DN, Chick J, Good AM, Kelly CA, Masterton G.

  Bateman DN, et al.
  Eur J Clin Pharmacol. 2004 May;60(3):221-4. doi: 10.1007/s00228-004-0748-x. Epub 2004 Apr 9.
  Eur J Clin Pharmacol. 2004.

  PMID: 15083251

• New generation antidepressants for depression in children and adolescents: a network meta-analysis.

  Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB, Cox GR, Merry SN, Meader N.

  Hetrick SE, et al.
  Cochrane Database Syst Rev. 2021 May 24;5(5):CD013674. doi: 10.1002/14651858.CD013674.pub2.
  Cochrane Database Syst Rev. 2021.

  PMID: 34029378
  Free PMC article.

• A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants.

  Rizo C, Deshpande A, Ing A, Seeman N.

  Rizo C, et al.
  J Affect Disord. 2011 Apr;130(1-2):290-3. doi: 10.1016/j.jad.2010.07.027. Epub 2010 Aug 12.
  J Affect Disord. 2011.

  PMID: 20705344

• Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.

  Masand PS, Gupta S.

  Masand PS, et al.
  Ann Clin Psychiatry. 2002 Sep;14(3):175-82. doi: 10.1023/a:1021141404535.
  Ann Clin Psychiatry. 2002.

  PMID: 12585567

  Review.

• Dual action antidepressants and some important considerations.

  Gupta RK, Tiller JW, Burrows GD.

  Gupta RK, et al.
  Aust N Z J Psychiatry. 2003 Apr;37(2):190-5. doi: 10.1046/j.1440-1614.2003.01169.x.
  Aust N Z J Psychiatry. 2003.

  PMID: 12656958

  Review.

See all similar articles

Cited by

• Long-Term Treatment with Trazodone Once-A-Day (TzOAD) in Patients with MDD: An Observational, Prospective Study.

  Shrashimirova M, Tyanev I, Cubała WJ, Wichniak A, Vodickova-Borzova C, Ruggieri A, Bonelli A, Lipone P, Comandini A, Cattaneo A.

  Shrashimirova M, et al.
  Neuropsychiatr Dis Treat. 2023 May 12;19:1181-1193. doi: 10.2147/NDT.S399948. eCollection 2023.
  Neuropsychiatr Dis Treat. 2023.

  PMID: 37201102
  Free PMC article.

• Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss.

  Durell N, Franks R, Coon S, Cowart K, Carris NW.

  Durell N, et al.
  J Pharm Technol. 2022 Oct;38(5):283-288. doi: 10.1177/87551225221110850. Epub 2022 Jul 29.
  J Pharm Technol. 2022.

  PMID: 36046348

• Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE Study.

  De Filippis S, Pugliese A, Christensen MC, Rosso G, Di Nicola M, Simonsen K, Ren H.

  De Filippis S, et al.
  Neuropsychiatr Dis Treat. 2022 Aug 9;18:1665-1677. doi: 10.2147/NDT.S375294. eCollection 2022.
  Neuropsychiatr Dis Treat. 2022.

  PMID: 35971416
  Free PMC article.

• Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.

  Ricardo-Silgado ML, Singh S, Cifuentes L, Decker PA, Gonzalez-Izundegui D, Moyer AM, Hurtado MD, Camilleri M, Bielinski SJ, Acosta A.

  Ricardo-Silgado ML, et al.
  BMC Med. 2022 Jul 26;20(1):261. doi: 10.1186/s12916-022-02433-x.
  BMC Med. 2022.

  PMID: 35879764
  Free PMC article.

• Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study.

  Mattingly GW, Ren H, Christensen MC, Katzman MA, Polosan M, Simonsen K, Hammer-Helmich L.

  Mattingly GW, et al.
  Front Psychiatry. 2022 Mar 9;13:824831. doi: 10.3389/fpsyt.2022.824831. eCollection 2022.
  Front Psychiatry. 2022.

  PMID: 35356713
  Free PMC article.

See all “Cited by” articles

MeSH terms

Substances

Retrospective analysis of the effect of weight on the efficacy of desvenlafaxine 50 and 100 mg/day in patients with depression

Choice of antidepressant. Focus on the needs of the patient Top page topics

12/29/2016

According to the literature, the incidence of obesity among people with depression is higher than in the general population. Meta-analyses (F.S. Luppino et al., 2010; L. de Wit et al., 2010) have shown that just as obesity is associated with an increased risk of depression, depression is also a predictor of overweight and obesity. The relationship between them is complicated by antidepressants, which often cause weight gain, which can adversely affect adherence to therapy. Although achieving remission is the most important goal in the management of patients with major depressive disorder (MDD), weight-neutral drugs are recommended among antidepressants with comparable efficacy, especially when it comes to patients who are overweight or obese. Finally, baseline body mass index (BMI) can influence both body weight changes during antidepressant treatment and the effectiveness of therapy.

Desvenlafaxine (used as desvenlafaxine succinate) is a serotonin and norepinephrine reuptake inhibitor (SNRI) approved for the treatment of adult patients with MDD. The main objectives of this analysis were to assess the effect of baseline BMI on treatment efficacy and weight dynamics in adults with MDD treated with desvenlafaxine 50 mg or 100 mg/day compared with placebo.

Materials and methods

The analysis included individual data from participants in 8 short-term, multicenter, randomized, double-blind, placebo-controlled studies investigating the efficacy of a fixed dose of desvenlafaxine in MDD. The duration of 6 studies was 8 weeks, one study lasted 10 and 12 weeks. The primary endpoint of all studies was change from baseline in the Hamilton Depression Rating Scale (HDRS-17).

Separately, a 12-month randomized trial was analyzed to assess weight changes only during desvenlafaxine therapy. In this study, patients first received open-label desvenlafaxine 50 mg/day for 8 weeks, after which responders continued open-label therapy for an additional 12 weeks. Patients with sustained improvement were then enrolled in a 6-month, double-blind, placebo-controlled study and randomized into two groups (1:1), one of which continued desvenlafaxine and the other was switched to placebo.

For inclusion criteria, all studies included adult outpatients with a diagnosis of MDD according to DSM-IV criteria, duration of depressive symptoms of at least 30 days, HDRS-17 score ≥20, or Montgomery Asberg Scale (MADRS). ) ≥25 points. The exclusion criteria in each study assumed the selection of medically stable patients with a primary diagnosis of MDD (excluding bipolar and psychotic depression).

Results

In short-term studies, a total of 3399 patients took at least one dose of study drug and were included in the pooled retrospective safety analysis. Of these, 2/3 were overweight or obese. So, in 1131 patients (33.3%), BMI was in the normal range or below normal; 964 (28.4%) were overweight; 1304 (38.4%) were obese. At least one efficacy evaluation was obtained in 3384 patients who constituted the ITT population (1122 normal or underweight, 960 overweight and 1302 obese).

The long-term, open-label study included 874 patients, including 345 (39.5%) normal weight, 271 (31.0%) overweight, and 258 (29.5%) obese. Randomized to continue therapy or placebo after completion of the open-label phase 548 patients, of which 542 had at least one assessment of body weight over time; these patients were included in the weight change analysis.

Baseline demographic and clinical characteristics were generally comparable between treatment groups in all studies.

Efficiency

After 8 weeks of therapy, improvement in HDRS-17 score from baseline was significantly greater with desvenlafaxine 50 and 100 mg/day compared with placebo in all BMI subgroups (all p≤0.0027, Fig.). The same results were obtained when evaluating the effectiveness of the MADRS scale and the Global Clinical Impression of Disease Severity Scale (CGI-S). Treatment response rates (as measured by change in HDRS-17 score) at 8 weeks were significantly higher for both doses of desvenlafaxine compared with placebo in each BMI subgroup.

Baseline BMI was a significant predictor of change in HDRS-17 score (higher BMI = less change in HDRS-17) for desvenlafaxine 50 mg/day (p=0.048) and 100 mg/day (p=0.031), but not placebo (p= 0.097). Also, baseline BMI was a significant predictor of response to desvenlafaxine 50 mg/day (p = 0.0397): patients with higher BMI were less likely to respond to treatment compared with patients with lower BMI. At the same time, the baseline BMI did not affect the likelihood of achieving remission or the time to response to therapy.

Change in body weight

In a pooled analysis of short-term studies, there was slight weight loss in each of the BMI subgroups at 8 and 16 weeks after initiation of therapy in patients treated with desvenlafaxine 50 or 100 mg/day. At the same time, normal and overweight patients in the placebo group showed a small but statistically significant increase in weight over time. The difference in weight change from baseline between the open-label (desvenlafaxine 50 and 100 mg/day) and placebo groups was small but statistically significant (p≤0.0195 in all subgroups). Baseline BMI was a significant predictor of change in weight and BMI in the general study population (p≤0.0035) and in the desvenlafaxine 100 mg/day group (p≤0.0354).

In an open-label, long-term study, desvenlafaxine 50 mg/day initially resulted in a decrease and then a slight increase in body weight (mean 0.47 kg from baseline). As for the subgroup analysis, after 8 weeks of desvenlafaxine 50 mg/day in the open-label phase of the study, in subjects with normal and overweight, there was no statistically significant change in body weight from baseline, and in patients with obesity, it significantly decreased (-0.38 ±0.15 kg; p=0.012). After 20 weeks of the open phase, in persons with initially normal and overweight, body weight slightly increased (+0.67±0.18 kg and +0.58±0.19kg, respectively, all p≤0. 003 compared with baseline), and did not change significantly in obese individuals.

During the double-blind phase of the study, there was significantly less weight gain with continued treatment with desvenlafaxine 50 mg/day compared to placebo (0.24 vs. 0.52 kg, respectively, p = 0.004). In subjects of normal weight at baseline, but not in those who were overweight or obese, desvenlafaxine was associated with small but statistically significant weight gain over the 26 weeks of the double-blind phase (0.97±0.26 kg, p<0.001). However, no statistically significant difference was found between patients treated with desvenlafaxine and placebo in any BMI subgroup.

Baseline BMI was a significant predictor of change in weight and BMI in the general long-term study population (all p≤0.009) and in the desvenlafaxine 50 mg/day group (all p≤0.0112). Patients with higher baseline BMI and obesity in particular were less likely to gain weight in the long term.

Talk

The results of this analysis are consistent with other studies and meta-analyses showing slightly lower efficacy of antidepressant therapy (selective serotonin reuptake inhibitors (SSRIs), SNRIs, tricyclic antidepressants, mirtazapine) in obese and overweight patients compared to normal weight individuals.

Body weight changes during desvenlafaxine therapy shown in this analysis are consistent with data for desvenlafaxine at doses up to 400 mg/day in other studies, as well as with studies of duloxetine, venlafaxine and some SSRIs (fluoxetine, paroxetine). In long-term studies (≥4 months), early weight loss was followed by a subsequent return to baseline body weight in patients treated with duloxetine or SSRIs.

The association between baseline BMI and weight change over time observed in this analysis (patients with high baseline BMI had more weight loss at baseline and less weight gain in the long term) is also consistent with findings from studies of other antidepressants.

Terminals

Desvenlafaxine 50 and 100 mg/day is effective in reducing depressive symptoms at any baseline BMI.
In all BMI subgroups, desvenlafaxine was associated with statistically significant weight loss (<1 kg) after short-term MDD therapy and did not cause significant weight changes compared with placebo after long-term treatment.
Baseline BMI was a predictor of response to treatment and weight change during treatment: slightly greater reductions in depressive symptoms were observed in patients with normal BMI, and short-term weight loss was greatest in obese patients.

Translation from English Vyacheslav Kilimchuk

The list of references is under revision.

R.S. McIntyre, R.S. Fayyad, C.J. Guico-Pabia, M. Boucher. A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d. Prim Care Companion CNS Disord. 2015; 17(3): 10.

• Current topic:
• Choice of antidepressant. Focus on the needs of the patient

Antidepressant Egis Velaxin (venlafaxine) 75 MG – “A lot of oddities, side effects, but it’s worth it”

Before using medicines, consult a specialist.

After unsuccessful treatment with the antidepressant Selectra, I switched to Velaxin. My diagnosis sounds like a moderate depressive episode with somatic symptoms. I had the following symptoms:

1. Constantly bad mood, depression.
2. Heaviness “on the soul”.
3. Insomnia and drowsiness at the same time.
4. Constant fatigue.

Replacement of Selektra with Velaksin happened at once. I immediately started drinking 75 mg.

I don’t understand why almost all antidepressants are sold in 28 pills. Can’t make 30?

After the first dose, about an hour later, my pupils dilated. Vision blurred, it was impossible to read, his eyes hurt and watery. In the future, my vision remained blurred, but I got used to it. With the pupils, everything is fine, it’s just that the eyes focus more slowly on the image.

Bitter tablets. They don’t share, but I did. It is not comfortable. Sometimes the pill turned into porridge and had to be eaten, but bitter. For the price, the tablets could be better.

The dosage was raised gradually. I felt better with the first 75mg tablet. But over time, the effect weakened and the severity returned, fatigue did not go anywhere. So my two doctors and I came up with a dose of 225 mg. This is the maximum dose that I drank in this form.

For all the time I had several side effects:

1. Blurred vision, I already wrote about this.
2. Dry mouth. I drink more than before.
3. Constipation. This is a real problem, because of which the doctor even considered changing the antidepressant. Because I go to the toilet once a week. This, unfortunately, is normal for antidepressants, but not normal for humans. I save myself with dufalac, donat, probiotics. But it is difficult and does not always help. If earlier probiotics with 500,000 bacteria helped me, now even a billion does not work. But at the very least I somehow support the intestines.
4. Cystitis. In 24 years of my life, I have never had cystitis. And then there were two cystitis in two months and two times of antibiotics. The doctors confirmed that it could be due to the antidepressants. They lower the immune system. There were no hypothermia, everything starts abruptly and unexpectedly.
5. Lack of libido. For me, this is irrelevant, but know that there is such a side effect.
6. Weight set. I gained 6 kg in three months, but then the weight began to fall back.
7. Cycle disorders. It goes any way.
8. At the beginning of the intake, sweating appeared at night. I woke up all wet. It only got easier after about 4 months.
9. All parts of the body began to twitch when falling asleep.
10. Heart stops also when falling asleep.

A lot of just oddities were also observed.

1. Food intolerance. For several months I ate only Nesquik chocolate balls with milk. This was my lunch and dinner. I can’t stand the smell and taste of meat, I don’t want potatoes, pasta, all sorts of cereals. I can’t stand the smell of soups. Like this.
2. Sound intolerance. I stopped listening to music. At first I stopped listening to songs, then music without words. I watch YouTube with subtitles. Asmr videos where they cut soap and make slimes, I also watch without sound. I don’t watch movies or series.
3. Sometimes there is short-term sadness. I have had this all my life, when for a few seconds there is heaviness and the world fades. But that was rare. And on Velaksin once every few days.
4. At a certain dose it was terribly boring. I languished, I had nowhere to put myself. A terrible feeling when you don’t want anything, there is no interest in anything, there are no plans in your head. It went away when the dose was increased to 150, but still occurs more often than before.
5. No longer cold outside. Now I’m constantly hot. I wear less clothes.

From the good:

1. Velaxin has a good effect on mood. I drink it with fluanxol, and together they give indifference, even mood, lack of anxiety. It’s like I’m in a vacuum, protected from all dangers.
2. Serotonin and norepinephrine reuptake inhibitors are good pain relievers. I have chronic pelvic pain, my stomach hurts during menstruation and my chest. My chest stopped hurting at all. The stomach hurts much less. Sometimes I don’t even take painkillers. Antidepressants are good for endometriosis. Perhaps I have it. That’s why I’m afraid to quit.
3. I stopped missing people and regretting the past. These thoughts just don’t come up. Or rarely.
4. Thoughts in the style of “I’m stupid, I can’t do anything, everything is bad” are gone.
5. I completed my master’s degree at Velaksin. If it wasn’t for him… I wanted to take a sabbatical.
6. Life just became more fun. At first, the mood turned from bad to indifferent. But over time it got better.

What Velaxin couldn’t handle. He didn’t give me the amount of energy I needed. I was terribly tired, short of breath. There was no moral and physical strength sometimes for something. I have been an asthenic all my life. But I’ve also been depressed all my life.

At the maximum dosage of 225 mg, it was not possible to achieve complete remission. Somewhere all the time something was missing. And the doctor last time increased the dosage to 300 mg, and then I began to drink prolong.

Despite all the oddities and side effects, I didn’t want to change Velaxin. I feel like this is my drug. He brought me back to life.

I think that if Velaksin is prescribed to you, then feel free to try it. It is one of the most powerful antidepressants along with Paxil. I didn’t have any “helicopters” on the way. The doctor in the day hospital was even surprised that I was immediately prescribed 75, and not 37.